Novo Nordisk diabetes drug works; no heart risk-FDA review

(Reuters) - Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.S. Food and Drug Administration concluded on Monday, sending the company's shares up 4 percent.